Adjustment of Immunosuppressants to Facilitate Anti-COVID-19 Antibody Production after mRNA Vaccination in Liver Transplant Recipients
Viruses · 2023
DOI: 10.3390/v15030678 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Wei-Chen Lee und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Liver and Transplantation Surgery, Department of General Surgery, Chang-Gung Memorial Hospital, Taoyuan 33357, Taiwan. Hauptthemen laut MEDLINE: Liver Transplantation, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chang-Gung Medical Foundation.
Abstract (Originalsprache)
Liver transplant recipients are immunocompromised and have low immunogenicity to produce antibodies in anti-COVID-19 vaccination. Whether immunosuppressant adjustment could facilitate anti-COVID-19 antibody production in anti-COVID-19 mRNA vaccination is undetermined. Our patients were informed to temporarily suspend mycophenolate mofetil (MMF) or everolimus (EVR) for 2 weeks during both the 1st and 2nd doses of Moderna mRNA-1273 vaccine. A total of 183 recipients receiving two doses of Moderna mRNA-1273 vaccine were enrolled and grouped into tacrolimus monotherapy (MT, n = 41), and dual therapy with non-adjustment (NA, n = 23), single suspension (SS, n = 19) and double suspension (DS, n = 100) of MMF/EVR in two-dose mRNA vaccination. A total of 155 (84.7%) patients had a humoral response to vaccines in this study. The humoral response rates were 60.9%, 89.5%, 91.0% and 80.5% in NA, SS, DS, and MT group patients, respectively (p = 0.003). Multivariate analysis showed that favorable factors for humoral response were temporary suspension of MMF/EVR and monotherapy, and unfavorable factors were deceased donor liver transplantation, WBC count < 4000/uL, lymphocyte < 20% and tacrolimus trough level ≥ 6.8 ng/mL. In conclusion, temporary two-week suspension of anti-proliferation immunosuppressants could create a window to facilitate antibody production during anti-COVID-19 mRNA vaccination. This concept may be applied to other vaccinations in liver transplant recipients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Liver and Transplantation Surgery, Department of General Surgery, Chang-Gung Memorial Hospital, Taoyuan 33357, Taiwan.
- Surgery, College of Medicine, Chang-Gung University, Taoyuan 33357, Taiwan.
- Department of Laboratory Medicine, Chang-Gung Memorial Hospital, Taoyuan 33357, Taiwan.
- Department of Medical Biotechnology and Laboratory Science, Chang-Gung University College of Medicine, Taoyuan 33357, Taiwan.
ORCID-Profile: Hao-Chien Hung, Jin-Chiao Lee, Chung-Guei Huang, Tsung-Han Wu, Ting-Jung Wu, Hong-Shiue Chou
Förderung
- Chang-Gung Medical Foundation
Zitieren
APA
Lee, W. C., Hung, H. C., Lee, J. C., Huang, C. G., Huang, P. W., Gu, P. W., Wang, Y. C., Cheng, C. H., Wu, T. H., Lee, C. F., Wu, T. J., Chou, H. S., & Chan, K. M. (2023). Adjustment of Immunosuppressants to Facilitate Anti-COVID-19 Antibody Production after mRNA Vaccination in Liver Transplant Recipients. Viruses. https://doi.org/10.3390/v15030678
Vancouver
Lee WC, Hung HC, Lee JC, Huang CG, Huang PW, Gu PW, et al. Adjustment of Immunosuppressants to Facilitate Anti-COVID-19 Antibody Production after mRNA Vaccination in Liver Transplant Recipients. Viruses. 2023. doi:10.3390/v15030678
BibTeX
@article{Lee2023,
author = {Lee, Wei-Chen and Hung, Hao-Chien and Lee, Jin-Chiao and Huang, Chung-Guei and Huang, Po-Wei and Gu, Po-Wen and Wang, Yu-Chao and Cheng, Chih-Hsien and Wu, Tsung-Han and Lee, Chen-Fang and Wu, Ting-Jung and Chou, Hong-Shiue and Chan, Kun-Ming},
title = {Adjustment of Immunosuppressants to Facilitate Anti-COVID-19 Antibody Production after mRNA Vaccination in Liver Transplant Recipients},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15030678}
}
EUVIMED